TISSUE PLASMINOGEN ACTIVATOR SUBSTITUTION VARIANT

摘要

Biologically active tissue plasminogen activator (t-PA) variants with greatly increased clot lysis activity as compared to wild-type t-PA are prepared, wherein the arginine residue at position 299 is replaced by an aspartic acid residue. DNA sequences can be prepared that encode the variants, as well as expression vectors incorporating the DNA sequences and host cells transformed with the expression vectors. The variants may be used in pharmaceutical preparations to treat a vascular disease or condition, or to prevent fibrin deposition or adhesion formation or reformation in mammals.